New drugs for the treatment of hypercholesterolaemia

Expert Opinion on Investigational Drugs

Volumn 12, Issue 11, 2003, Pages 1777-1789

  Iglesias, Pedro ^a   Díez, Juan J ^b  

^a HOSPITAL GENERAL DE SEGOVIA   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Avasimibe; Colesvelam; Ezetimibe; Implitapide; Pitavastatin; Rosuvastatin

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; AVASIMIBE; BILE ACID; COLESEVELAM; CYCLOSPORIN; CYTOCHROME P450 3A4; EZETIMIBE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; IMPLITAPIDE; KN 104; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PD 148515; PITAVASTATIN; PRAVASTATIN; PROBUCOL; RESIN; REXINOID; ROSUVASTATIN; SHINOGI; SIMVASTATIN; STEROL DERIVATIVE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERY LOW DENSITY LIPOPROTEIN; WARFARIN;

CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CHOLESTEROL SYNTHESIS; CLINICAL TRIAL; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG RESEARCH; DRUG SELECTIVITY; HEMATURIA; HOMEOSTASIS; HUMAN; HYDROPHILICITY; HYPERCHOLESTEROLEMIA; INTESTINE ABSORPTION; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; LIPOPROTEIN BLOOD LEVEL; LIVER; LIVER TOXICITY; METABOLIC INHIBITION; MONOTHERAPY; MORBIDITY; MORTALITY; MUSCLE DISEASE; MUSCLE WEAKNESS; NONHUMAN; PATIENT COMPLIANCE; PROTEINURIA; REVIEW; STOMACH PAIN; STRUCTURE ACTIVITY RELATION;

ABSORPTION; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; CLINICAL TRIALS; CORONARY DISEASE; DRUG DESIGN; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; INTESTINES;

EID: 10744230409     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.12.11.1777     Document Type: Review

References (128)

1. CHEN Z, PETO R, COLLINS R et al.: Serum cholesterol concentration and coronary heart disease in a population with low cholesterol levels. Br. Med. J. (1991) 303:276-282.
2. VERSCHUUREN WM, JACOBS DR, BLOEMBERG B et al.: Serum total cholesterol and long-term coronary heart disease mortality in different culture: twenty five year follow up of the seven countries study. JAMA (1995) 274:131-136.
3. ASSMANN G, CULLEN P, SCHULTE H: The Munster Heart Study (PROCAM): results of follow up at 8 years. Eur. Heart J. (1998) 19(Suppl. A)A2-A11.
4. DAYTON S, PEARCE ML, HASHIMOTO S et al.: A controlled clinical trial of a diet high in unsatured fat in preventing complications of atherosclerosis. Circulation (1969) 39(Suppl. II):1-63.
5. OLIVER MF, HEADY JA. MORRIS JN, COOPER J: A co-operative trial in the primary prevention of ischaemic heart disease using dofibrate. Report from the Committee of Principal Investigations. Br. Heart J. (1978) 40:1069-1118.
6. LIPID RESEARCH CLINICS PROGRAMS: The lipid research clinics coronary primary prevention trial results: I. Reduction in incidence of coronary heart disease. JAMA (1984) 251:351-364.
7. FRICK MH, ELO O, HAAPA K et al.: Helsinki heart study: primary-prevention trial with gemfibrozil in middle-age men with dyslipidemia. N. Engl. J. Med. (1987) 317:1237-1245.
8. SHEPHERD J, COBBE SM, FORD I et al.: Prevention of coronary heat disease with pravastatin in men with hypercholesterolemia. N. Engl. J. Med. (1995) 333:1301-1307.
9. DOWNS JR, CLEARFIELD M, WEIS S et al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA (1998) 279:1615-1622.
10. HEART PROTECTION STUDY COLLABORATIVE GROUP: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high risk individuals: a randomised placebo controlled trial. Lancet (2002) 360:7-22.
11. RESEARCH COMMITTEE TO THE MEDICAL RESEARCH COUNCIL: Controlled trial of soya-bean oil in myocardial infarction. Lancet (1968) 2(7570):693-700.
12. BURR ML, FEHILY AM, GILBERT JF et al.: effects of changes in fat, fish and fibre intakes on death and myocardial reinfaction: diet and reinfarction trial (DART). Lancet.(1989) 2(8666):757-761.
13. SCANDINAVIAN SIMVASTATIN SURVIVAL GROUP: Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet (1994) 334:1383-1389.
14. SACKS FM, PFEFFER MA, MOYE LA et al.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N. Engl. J. Med. (1996) 335:1001-1009.
15. THE LONG-TERM INTERVENTION WITH PRAVASTATIN IN ISCHAEMIC DISEASE (LIPID) STUDY GROUP: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and broad range of cholesterol levels. N. Engl. J. Med. (1998) 338:1349-1357.
16. PITT B, WATERS D, BROWN WV et al.: Aggressive lipid lowering therapy compared with angioplasty in stable coronary artery disease. N. Engl. J. Med (1999) 341:70-76.
17. SCHWARTZ GG, OLSSON AG, EZEKOWITZ MD et al.: Effects of atorvastatin on early recurrent ischaemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA (2001) 285:1711-1718.
18. SERRUYS PWJC, DE FEYTER P, MACAYA N et al.: Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention.JAMA (2002) 287:3215-3222.
19. LEVY RI: A quarter century of drug treatment of dyslipoproteinemia, with a focus on the new HMG-CoA reductase inhibitor fluvastatin. Circulation (1993) 87(Suppl. 4):III45.
20. JONES P, KAFONEK S, LAURORA I et al: Comparative dose efficay study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am. J. Cardiol. (1998) 81:582-587.
21. HOERGER TJ, BALA MV, BRAY JM, WILCOSKY TC, LAROSA J: Treatment patterns and distribution of low-density lipoprotein cholesterol levels in treatmenteligible United States adults. Am. J. Cardiol (1998) 82:61-65.
22. PEARSON TA, LAURORA I, CHU H, KAFONEK S: The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low density lipoprotein goals.Arch. Intern. Med. (2000) 160:459-467.
23. EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS: Executive summary of the third report of the national cholesterol education program (NECP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III).JAMA (2001) 285:2486-2497.
24. BROWN WV: Novel approaches to lipid lowering: what is on the horizon? Am. J. Cardiol. (2001) 87(Suppl.):23B-27B.
25. BRUCKERT E: New advances in lipid-modifying therapies for reducing cardiovascular risk. Cardiology (2002) 97:59-66.
26. EVANS M, ROBERTS A, REES A: The future direction of cholesterol-lowering therapy. Curr. Opin. Lipidol. (2002) 13:663-669.
27. SUDHOP T, BERGMANN KV: Cholesterol absorption inhibitors for the treatment of hypercholesterolemia. Drugs (2002) 62:2333-2347.
28. McKENNEY JM: New cholesterol guidelines, new treatment challenges. Pharmacotherapy (2002) 22:853-863.
29. GOTTO AM Jr: Treating hypercholesterolemia: looking forwad. Clin. Cardiol. (2003) 26(Suppl. I):121-128.
30. BRUCKERT E: New lipid-modifying therapies Expert Opin. Investig. Drugs (2003) 12:325-335.
31. DIETSCHY JM, TURLEY SD, SPADY DK: Role of liver in the maintenance of cholesterol and low density lipoprotein homeostasis in different animal species, including humans. J. Lipid Res. (1993) 34:1637-1659.
32. BOSNER MS, LANGE LG, STENSON WF, OSTLUND RE Jr: Percent cholesterol absorption in normal women and men quantified with dual stable isotopic tracers and negative ion mass spectrometry. J. Lipid Res. (1999) 40:302-308.
33. HUSSAIN MM: A proposed model for the assembly of chylomicrons. Atherosclerosis (2000) 148:1-15.
34. OSTLUND RE Jr: Cholesterol absorption. Curr. Opin. Gastroenterol. (2002) 18:254-258.
35. DAWSON PA, RUDEL LL: Intestinal cholesterol absorption. Curr. Opin. Lipidol. (1999) 10:315-320.
36. SHEPHERD J: The role of the exogenous pathway in hypercholesterolemia. Eur. Heart. J. (2001) 3(Suppl. E):E2-E5.
37. REPA JJ, TURLEY SD, LOBACCARO JMA et al.: Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. Science (2000) 289:1524-1529.
38. TAKEMOTO M, LIAO JK: Pleitropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler. Thromb. Vasc. Biol. (2001) 21:1712-1719.
39. McTAGGART F, BUCKETT L, DAVIDSON R et al.: Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy-3-methyl-glutarylcoenzyme A reductase inhibitor. Am. J. Cardiol. (2001) 87(Suppl. 5a):28B-32B.
40. WHITE CM: A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin. J. Clin. Pharmacol. (2002) 42:963-970.
41. CARSWELL CI, PLOSKER GL, JARVIS B: Rosuvastatin. Drugs (2002) 62:2075-2085.
42. OLSSON AG, McTAGGART F, RAZA ALI: Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor. Cardiovasc. Drug Rev. (2002) 20:303-328.
43. DAVIDSON MH: Rosuvastatin: a highly efficacious statin for the treatment of dyslipidaemia. Expert Opin. Investig. Drugs. (2002)11:125-141.
44. CHENG-LAI A. Rosuvastatin: a new HMG-CoA reductase inhibitor for the treatment of hypercholesterolemia. Heart Dis. (2003) 5:72-78.
45. RADER DJ, DAVIDSON MH, CAPLAN RJ, PEARS JS: Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin. Am. J. Cardiol. (2003) 6:20C-23C.
46. SHEPHERD J, HUNNINGHAKE DB, BARTER P, McKENNEY JM, HUTCHINSON HG: Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals.Am. J. Cardiol. (2003) 6:11C-17C.
47. IGEL M, SUDHOP T, VON BERGMANN K: Pharmacology of 3-hydroxy-3-methyl-glutarylcoenzyme A reductase inhibitors (statins) including rosuvastatin and pitavastatin. J. Clin. Pharmacol.(2002) 42:835-845.
48. NESS CG, ZHAO Z, LOPEZ D: Inhibitors of cholesterol biosynthesis increase hepatic low density lipoprotein receptor protein degradation. Arch. Biochem. Biophys. (1996) 325:242-248.
49. CHONG PH, YIM BT: Rosuvastatin for the treatment of patients with hypercholesterolemia. Ann. Pharmacother. (2002) 36:93-101.
50. WARWICK MJ, DANE AL, RAZA A et al.: Pharmacokinetic and safety profile for the new HMG-CoA reductase inhibitor ZD4522 (single and multiple doses). Can. J. Cardiol. (2000) 16(Suppl. F):19F.
51. MARTIN PD, DANE AL, SCHNECK DW et al.: Pharmacodynamic effects and pharmacokinetics of new HMG-CoA reductase inhibitor ZD4522 after AM and PM administration in healthy subjects. J. Clin. Pharmacol. (2000) 40:1056.
52. ROACH AE, TSIKOURIS JP, HAASE KK: Rosuvastatin. A new HMG-CoA reductasa inhibitor for hypercholesterolemia. Formulary (2002) 37:179-185.
53. OLSSON AG, PEARS J, McKELLAR J, MIZAN J, RAZA A. Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia. Am. J. Cardiol. (2001) 88:504-508.
54. PAOLETTI R, FAHMY M, MAHLA G, MIZAN J, SOUTHWORTH H: Rosuvastatin demonstrates greater reduction of low-density lipoprotein cholesterol compared with pravastatin and simvastatin in hypercholesterolaemic patients: a randomized, double-blind study. J. Cardiovasc. Risk (2001) 8:383-390.
55. OLSSON AG, ISTAD H, LUURILA O et al.: Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia. Am. Heart J. (2002) 144:1044-1051.
56. BROWN WV, BAYS HE, HASSMAN DR et al.: Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial. Am. Heart J. (2002) 144:1036-1043.
57. DAVIDSON M, MA P, STEIN EA et al.: Comparison of effects of low-density lipoprotein cholesterol and high-desity lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with Type IIa or IIb hypercholesterolemia. Am. J. Cardiol. (2002) 89:268-275.
58. BREWER HB Jr: Benefit-risk assessment of rosuvastatin 10 to 40 milligrams. Am. J. Cardiol. (2003) 92:23K-29K
59. JONES PH, DAVIDSON MH, STEIN EA et al.: Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am. J. Cardiol. (2003) 92:152-160.
60. SCHUSTER H: Rosuvastatin - a highly effective new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor: review of clinical data at 10-40 mg doses in dyslipidemic patients. Cardiology (2003) 99:126-139.
61. BERRY DAM, BERRY SM, MCKELLAR J, PEARSON TA: Comparison of the dose-response relationships of 2 lipid-lowering agents: a Bayesian meta-analysis. Am. Heart J. (2003) 145:1036-1045.
62. STALKER TJ, LEFER AM, SCALIA R: A new HMG-CoA reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects on the microvascular endothelium: the role of mevalonic acid. Br. J. Pharmacol. (2001) 133:406-412.
63. KNOPP RH: Drug treatment of lipid disorders. N. Engl J. Med. (1999) 341:498-511.
64. FLORES NA: Pitavastatin. Curr. Opin. Investig. Drug (2002) 3:1334-1341.
65. KAJINAMI K, MABUCHI H, SAITO Y: NK-104: a novel synthetic HMG-CoA reductase inhibitor. Expert Opin. Investig. Drugs (2000) 9:2653-2661.
66. ISLEY WL: Pitavastatin (NK-104), a new HMG-CoA reductase inhibitor. Drugs Today (2001) 37:587-594.
67. KOJIMA J, FUJINO H, YOSIMURA M, MORIKAWA H, KIMATA H: Simultaneous determination of NK-104 and its lactone in biological samples by column-switching high-performance liquid chromatography with ultraviolet detection. J. Chromatogr. B. Biomed, Sci. Appl. (1999) 724:173-180.
68. KAJINAMI K, KOIZUMI J, UEDA K et al.: Effects of NK-104, a new hydroxymethylglutaryl-coenzyme reductase inhibitor, on low-density lipoprotein cholesterol in heterozygous familial hypercholesterolemia. Am. J. Cardiol. (2000) 85:178-183.
69. SAITO Y, YAMADA N, TERAMOTO T et al.: A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia. Atherosclerosis (2002) 162:373-379.
70. SAITO Y, YAMADA N, TERAMOTO T et al.: Clinical efficacy of pitavastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor in patients with hyperlipidemia. Dose-finding study using the double-blind, three-group parallel comparison. Arzneimittelforschung (2002) 52:251-255.
71. NOJI Y, HIGASHIKATA T, INAZU A et al.: Long-term treatment with pitavastatin (NK-104), a new HMG-CoA reductase inhibitor, of patients with heterozygous familial hypercholesterolemia. Atherosclerosis (2002) 163:157-164.
72. NEIL HA, MEIJER GW, ROE LS: Randomised controlled trial of use by hypercholesterolaemic patients of a vegetable oil sterol-enriched fat spread. Atherosclerosis (2001) 156:329-337.
73. LAW M: Plant sterol and stanol margarines and health. Br. Med. J. (2001) 320:861-864.
74. BEIL FU, GRUNDY SM: Studies on plasma lipoproteins during absorption of exogenous lecithin in man. J. Lipid Res. (1980) 21:525-536.
75. JANDACEK RJ, RAMIREZ MM, CROUSE JR 3rd: Effects of partial replacement of dietary fat by olestra on dietary cholesterol absorption in man. Metabolism (1990) 39:848-852.
76. GYLLING H, MIETTINEN TA: The effect of cholesterol absorption inhibition on low density lipoprotein cholesterol level. Atherosclerosis (1995) 117:305-308.
77. MITTENDORFER B, OSTLUND RE Jr, PATTERSON BW, KLEIN S: Orlistat inhibits dietary cholesterol absorption. Obes. Res. (2001) 9:599-604.
78. VAN HEEK M, FARLEY C, COMPTON DS, HOOS LM, SMITH-TORHAN A. DAVIS HR: Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function. Br. J. Pharmacol. (2001) 134:409-417.
79. CATAPANO AL: Ezetimibe: a selective inhibitor of cholesterol absorption. Eur. Heart J. (2001) 3(Suppl. E):E6-E10.
80. GUPTA EK, ITO MK: Ezetimibe: the first in a novel class of selective cholesterol-absorption inhibitors. Heart Dis. (2002) 4:399-409.
81. BAYS H: Ezetimibe. Expert Opin. Investig. Drugs (2002) 11:1587-1604.
82. DARKES MJM, POOLE RM, GOA KL: Ezetimibe. Am. J. Cardiovasc. Drugs (2003) 3:67-76.
83. SUDHOP T, LÜTJOHANN D, KODAL A et al.: Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation (2002) 106:1943-1948.
84. BAYS HE, MOORE PB, DREHOBL MA et al.: Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase studies. Clin. Ther. (2001) 23:1209-1230.
85. PATRICK JE, KOSOGLOU T, STAUBER KL et al.: Disposition of the selective cholesterol absorption inhibitor ezetimibe in healthy male subjects. Drug Metab. Dispos. (2002) 30:430-437.
86. VAN HEEK M, DAVIS H: Pharmacology of ezetimibe. Eur. Heart J. Suppl. (2002) 4(Suppl. J)J17-J20.
87. VAN HEEK M, FARLEY C, COMPTON DS et al.: Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663. Br. J. Pharmacol. (2000) 129:1748-1754.
88. ZHU Y, STATKEVICH P, KOSOGLOU T et al.: Effects of ezetimibe (SCH 58235) on the activity of drug metabolizing enzymes in vivo. Clin. Pharmacol. Ther. (2000) 67:152.
89. EZZET F, WEXLER D, STATKEVICH P et al.: The plasma concentrations and LDL-C relationship in patients receiving ezetimibe. J. Clin. Pharmacol. (2001) 41:943-949.
90. VAN HEEK M, FARLEY C, COMPTON DS et al.: The potent cholesterol absorption inhibitor, ezetimibe, is glucuronidated in the intestine, localizes to the intestine, and circulates enterohepatically. Atherosclerosis (2000) 151:155A.
91. KNOPP RH, GITTER H, TRUITT T et al.: Ezetimibe reduces low-density lipoprotein cholesterol: results of a Phase III, randomized, double-blind, placebo-controlled trial. Atherosclerosis (2001) 2(Suppl. 2):38A.
92. DUJOVNE CA, ETTINGER MP, McNEER JF et al.: Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am. J. Cardiol (2002) 90:1092-1097.
93. GAGNÉ C, BAYS HE, WEISS SR et al.: Efficacy and safety of ezetimibe added to ongoing star n therapy for treatment of patients with primary hypercholesterolemia. Am. J. Cardiol (2002) 90:1084-1091.
94. GAGNÉ C, GAUDET D, BRUCKERT E. THE EZETIMIBE STUDY GROUP: Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation (2002) 105:2469-2475.
95. DAVIDSON MH, McGARRY T, BETTIS R et al.: Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J. Am. Coll. Cardiol. (2002) 40:2125-2134.
96. BAYS HE, WEISS S, GAGNÉ C et al.: Ezetimibe added to ongoing statin therapy for treatment of primary hypercholesterolemia. J. Am. Coll. Cardiol (2002) 39(5, Suppl. A):833-834.
97. LIPKA L, KERZNER B, CORBELLI J et al.: Ezetimibe coadministered with lovastatin in patients with primary hypercholesterolemia. J. Am. Coll. Cardiol. (2002) 39(Suppl. B):430B.
98. MELANI L, MILLS R, HASSMAN D et al.: Ezetimibe coadministered with pravastatin in 538 patients with primary hypercholesterolemia. J. Am. Coll. Cardiol. (2002) 39(Suppl. B): 139B.
99. BALLANTYNE C, HOURI J, NOTARBARTOLO A et al.: Ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia. J. Am. Coll. Cardiol. (2002) 39(5, Suppl. A):227A.
100. DAVIS HR Jr, PULA KK, ALTON KB et al.: The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-3-methylglutaryl coenzyme A reductase inhibitors in dogs. Metabolism (2001) 50:1234-1241.
101. SUCKLING KE, STANGE EF: Role of acyl-CoA: cholesterol acyltransferase in cellular cholesterol metabolism. J. Lipid Res. (1985) 26:647-671.
102. RUDEL LL, LEE RG, COCKMAN TL: Acyl coenzyme A. Cholesterol acyltransferase types 1 and 2: structure and function in atherosclerosis. Curr. Opin. Lipidol. (2001) 12:121-127.
103. OELKERS P, BEHARI A, CROMLEY D et al.: Characterization of two human genes encoding acyl coenzyme A: cholesterol acyltransferase-related enzymes. J. Biol. Chem. (1998) 273:26755-26764.
104. LLAVERIAS G, LAGUNA JC, ALEGRET M: Pharmacology of the ACAT inhibitor avasimibe (CI-1011). Cardiovasc. Drug Rev. (2003) 21:33-50.
105. LEE HT, SLISKOVIC DR, PICARD JA et al..: Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets. J. Med. Chem. (1996) 39:5031-5034.
106. RAMHARACK R, SPAHR MA, SEKERKE CS et al.: CI-1011 lowers lipoprotein (a) and plasma cholesterol concentrations in chow-fed cynomolgus monkeys. Atherosclerosis (1998) 136:79-87.
107. BURNETT JR, WILCOX LJ, TELFORD DE et al.: Inhibition of ACAT by avasimibe decreases both VLDL and LDL apolipoprotein B production in miniature pigs. J. Lipid Res. (1999) 40:1317-1327.
108. INSULL W Jr, TOTH P, MULLICAN W et al.: Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: a 24-week randomized controlled trial. Mayo Clin. Proc. (2001) 76:971-982.
109. DELSING DJ, OFFERMAN EH, VAN DUYVENVOORDE W et al.: Acyl-CoA. cholesterol acyltransferase inhibitor avasimibe reduces atherosclerosis in addition to its cholesterol-lowering effect in ApoE*3-Leiden mice. Circulation (2001) 103:1778-1786.
110. NICOLOSI RJ, WILSON TA, KRAUSE BR: The ACAT inhibitor, CI-101 1 is effective in the prevention and regression of aortic fatty steak area in hamsters. Atherosclerosis (1998) 137:77-85.
111. BOCAN TM, KRAUSE BR, ROSEBURY WS et al.: The combined effect of inhibiting both ACAT and HMG-CoA reductase may directly induce atherosclerotic lesion regression. Atherosclerosis (2001) 157:97-105.
112. RODRIGUEZ A, USHER DC: Anti-atherogenic effect of the acyl-CoA: cholesterol acyltransferase inhibitor, avasimibe (CI-1011), in cultured primary human macrophages. Atherosclerosis (2002) 161:45-54.
113. LLAVERIAS G, JOVE M, VAZQUEZ-CARRERA M et al: Avasimibe and atorvastatin synergistically reduce cholesterol ester content in THP-1 macrophages. Eur. J. Pharmacol. (2002) 451:11-17.
114. TARDIF JC, GREGOIRE J, LESPERANCE J et al.: Design features of the Avasimibe and Progression of coronary Lessions assessed by intravascular UltraSound (A-PLUS) clinical trial. Am. Heart J. (2002) 144:589-596.
115. GORDON DA, JAMIL H: Progress towards understanding the role of microsomal triglyceride transfer protein in apolipoprotein-B lipoprotein assembly Biochem. Biophys. Acta (2000) 1486:72-83.
116. CHANG G, RUGGERI RB, HARWOOD HJ Jr: Microsomal triglyceride transfer protein (MTP) inhibitors: discovery of clinically active inhibitors using high-throughput screening and parallel synthesis paradigms. Curr. Opin. Drug Discov. Devel. (2002) 5:562-570.
117. SHIOMI M, ITO T: MTP inhibitor decreases plasma cholesterol levels in LDL receptor-deficient WHHL rabbits by lowering the VLDL secretion. Eur. J. Pharmacol. (2001) 431:127-131.
118. DAVIDSON MH, DICKLIN MR, MAKI KC, KLEINPELL RM: Colesevelam hydrochloride: a non-absorbed, polymeric cholesterol-lowering agent. Expert Opin. Investig. Drugs (2000) 9:2663-2671.
119. ALDRIDGE MA, ITO MK: Colesevelam hydrochloride: a novel bile acid-binding resin. Ann. Pharmacother. (2001) 35:898-907.
120. STEINMETZ KL: Colesevelam hydrochloride. Am. J. Health Syst. Pharm. (2002) 15:932-939.
121. BAYS H, DUJOVNE C: Colesevelam HCI: a non-systemic lipid altering drug. Expert Opin. Pharmacother. (2003) 4:779-790.
122. DAVIDSON MH, DILLON MA, GORDON B et al.: Colesevelam hydrochloride (choletagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch. Intern. Med. (1999) 159:1893-1900.
123. INSULL W Jr, KOREN M, DAVIGNON J et al.: Efficacy and short-term safety of a new ACAT inhibitor, avasimibe, on lipids, lipoproteins, and apolipoproteins, in patients with combined hyperlipidemia. Atherosclerosis (2001) 157:137-144.
124. WONG NN: Colesevelam: a new bile acid sequestrant. Heart Dis. (2001) 3:63-70.
125. KNAPP HH, SCHROTT H, MA P et al.: Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. Am. J. Med. (2001) 110:352-360.
126. DAVIDSON MH, TOTH P, WEISS S et al.: Low-dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hypercholesterolemia. Clin. Cardiol. (2001) 24:467-474.
127. HUNNINGHAKE D, INSULL W Jr, TOTH P, DAVIDSON D, DONOVAN JM, BURKE SK: Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively. Atherosclerosis (2001) 158:407-416.
128. DONOVAN JM, STIPINSKI D, STILES MR, OLSON TA, BURKE SK: Drug interactions with colesevelam hydrochloride, a novel, potent lipid-lowering agent. Cardiovasc. Drug Ther. (2000) 14:681-690.